Document Detail


The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases.
MedLine Citation:
PMID:  15123036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This is a historical overview seen from a personal angle. It covers the insights made during the past 20 years into the destructive processes of rheumatoid arthritis (RA) related to cytokines. The biochemical knowledge of the matrix components (i.e. collagen) and enzymology (i.e. collagenase) available in the 1950s led to the identification of cells from synovial tissue producing collagenase (fibroblast-like cells) and their interaction with other immune cells, i.e. monocyte-macrophages (Mphi) and lymphocytes (1976-1979). This insight led to the isolation of soluble factors produced by Mphi, such as interleukin-1 (IL-1) and TNF, the principal cytokines inducing collagenase and PGE(2) in many target cells (i.e. synovial fibroblasts, chondrocytes, bone-derived cells) (1981-1985). Further advances resulted from observations that, in clinical conditions (i.e. leukaemia, juvenile RA), a remission of fever and inflammation may occur spontaneously and that tissue catabolism may persist despite the absence of systemic inflammation; this gave rise to the concept and identification of endogenous cytokine inhibitors (i.e. IL-1 receptor antagonist and TNF soluble receptor) (1984-1989). The fourth milestone was the observation that the production of IL-1 and TNF by Mphi was induced mainly by direct contact with lymphocytes, prompting studies of the ligands and counter-ligands on Mphi and lymphocytes as well as inhibitors involved in this cell-cell contact, some of these inhibitors being involved in lipid metabolism and acute-phase proteins (HDL-apo A-1).
Authors:
Jean-Michel Dayer
Related Documents :
21195166 - Activation of the maternal immune system induces endocrine changes in the placenta via ...
21556316 - Importance of innate mucosal immunity and the promises it holds.
21099216 - High-mobility group box protein 1: a novel mediator of inflammatory-induced renal epith...
17561986 - Major biological obstacles for persistent cell-based regeneration of articular cartilage.
22371766 - Environmental toxin 4-nonylphenol and autoimmune diseases: using dna microarray to exam...
24053946 - Roles of micrornas in the caenorhabditis elegans nervous system.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Best practice & research. Clinical rheumatology     Volume:  18     ISSN:  1521-6942     ISO Abbreviation:  Best Pract Res Clin Rheumatol     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-05-04     Completed Date:  2004-05-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101121149     Medline TA:  Best Pract Res Clin Rheumatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  31-45     Citation Subset:  IM    
Affiliation:
Division of Immunology and Allergy, University Hospital, 24, Rue Micheli-du-Crest, 1211 Geneva 14, Switzerland. jean-michel.dayer@hcuge.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute-Phase Proteins / drug effects,  metabolism
Animals
Cells, Cultured
Cytokines / drug effects*,  metabolism*
Female
Humans
Male
Receptors, Interleukin-1 / metabolism*
Research Design
Rheumatic Diseases / drug therapy*,  immunology,  pathology*
Sensitivity and Specificity
Synovial Membrane / enzymology,  metabolism
Tumor Necrosis Factor-alpha / drug effects,  metabolism
Chemical
Reg. No./Substance:
0/Acute-Phase Proteins; 0/Cytokines; 0/Receptors, Interleukin-1; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Corticosteroids--from an idea to clinical use.
Next Document:  The usefulness and the limitations of animal models in identifying targets for therapy in arthritis.